The latest, highly contagious variant has driven up hospitalization rates and deepened worries about waning immunity among those vaccinated or boosted months ago.
Neither Pfizer’s nor Moderna’s pediatric doses have been tested against the subvariants that may soon be dominant in the U.S.
Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nation’s youngest children.
Outside experts will meet next week to decide whether to recommend that the agency authorize the vaccine for kids 6 months and older.
A significantly stronger immune response against Omicron is seen, but it remains unclear how an updated vaccine will fare against future versions of the virus.
The findings indicate that the updated vaccine produced a significantly stronger immune response against Omicron, but it is unclear how it will fare against future versions of the virus.
The preliminary results appeared to show that three doses of the vaccine worked better than two.
Previously, the agency said those 50 and older could opt for the additional shot, but only encouraged people over 65 or with underlying medical conditions to get it.
More than eight million of the 28 million children in that age group in the United States have received two vaccine shots.
Given that the age group has the lowest coronavirus vaccination rate of all eligible Americans, public health experts are not expecting a rush for the booster.